Effect of Remote Ischemic Conditioning on Cerebral Hemodynamics in Patients After Intravenous Thrombolysis (RICCH-IVT)
Launched by YI YANG · Oct 25, 2022
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
In this study, cases of ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The RIC group receive basic treatment and remote ischemic conditioning for 200mmHg at 6 and 18-24 hours after intravenous thrombolysis. The sham-RIC group receive basic treatment and remote ischemic conditioning for 60mmHg at 6 and 18-24 hours after intravenous thrombolysis. Both groups underwent cerebral hemodynamics after RIC and recorded the relevant indexes. The investigators aimed to determine the effect of remote ischemic conditioning on cerebral hemodynamics in patie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥ 18 and \< 80 years, both sexes;
- • 2. a clear clinical diagnosis of acute ischemic stroke and treatment with standard rt-PA (0.9 mg/kg) IVT within 4.5 h of stroke onset;
- • 3. pre-onset modified Rankin Scale (mRS) score ≤1;
- • 4. baseline National Institute of Health Stroke Scale (NIHSS) score ≥5 and ≤25;
- • 5. Glasgow Coma Scale score ≥8.
- Exclusion Criteria:
- • 1. having received bridging therapy (IVT plus mechanical thrombectomy);
- • 2. previous history of atrial fibrillation or electrocardiographic evidence of atrial fibrillation;
- • 3. contraindications to RIC treatment or previous RIC treatment or similar treatment;
- • 4. pregnancy or breastfeeding;
- • 5. life expectancy of ≤3 months or inability to complete the study for other reasons;
- • 6. unwillingness to be followed up or poor treatment compliance or participation in other clinical studies;
- • 7. had insufficient bilateral temporal bone windows for insonation of the middle cerebral artery.
About Yi Yang
Yi Yang is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative drug development. With a focus on collaboration and scientific rigor, Yi Yang specializes in designing and managing clinical trials across various therapeutic areas, ensuring compliance with regulatory standards and ethical guidelines. The organization is committed to fostering partnerships with healthcare professionals and institutions to facilitate the timely delivery of safe and effective treatments. Through a patient-centered approach and a robust operational framework, Yi Yang strives to contribute to the advancement of healthcare and the well-being of communities globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Changchun, Jilin, China
Changchun, Jilin, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials